SG Americas Securities LLC Has $765,000 Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX

Key Points

• SG Americas Securities LLC cut its stake in Catalyst Pharmaceuticals by 60.8% in Q4, selling 50,914 shares and now holds 32,776 shares worth $765,000.
• Institutional ownership stands at 79.22%, with several funds (Federated Hermes, Y Intercept Hong Kong, Exchange Traded Concepts, Public Sector Pension Investment Board, Voya) materially increasing their positions in recent quarters.
• Analysts are broadly bullish: the consensus rating is Strong Buy with an average target of $34, and multiple brokers (including Citigroup, Zacks, Truist, Cantor Fitzgerald) have recently upgraded the stock or raised targets.

SG Americas Securities LLC lowered its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 60.8% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 32,776 shares of the biopharmaceutical company's stock after selling 50,914 shares during the period. SG Americas Securities LLC's holdings in Catalyst Pharmaceuticals were worth $765,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of CPRX. Federated Hermes Inc. increased its holdings in shares of Catalyst Pharmaceuticals by 52.8% during the 3rd quarter. Federated Hermes Inc. now owns 389,289 shares of the biopharmaceutical company's stock worth $7,669,000 after acquiring an additional 134,509 shares during the last quarter. Y Intercept Hong Kong Ltd lifted its holdings in Catalyst Pharmaceuticals by 1,216.5% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 165,496 shares of the biopharmaceutical company's stock valued at $3,260,000 after purchasing an additional 152,925 shares during the last quarter. Exchange Traded Concepts LLC boosted its position in Catalyst Pharmaceuticals by 3,559.0% during the third quarter. Exchange Traded Concepts LLC now owns 62,971 shares of the biopharmaceutical company's stock worth $1,241,000 after purchasing an additional 61,250 shares during the period. Public Sector Pension Investment Board boosted its position in Catalyst Pharmaceuticals by 10.8% during the third quarter. Public Sector Pension Investment Board now owns 516,745 shares of the biopharmaceutical company's stock worth $10,180,000 after purchasing an additional 50,343 shares during the period. Finally, Voya Investment Management LLC increased its holdings in shares of Catalyst Pharmaceuticals by 25.1% in the third quarter. Voya Investment Management LLC now owns 446,399 shares of the biopharmaceutical company's stock valued at $8,794,000 after purchasing an additional 89,498 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Performance

CPRX stock opened at $24.94 on Friday. Catalyst Pharmaceuticals, Inc. has a 52 week low of $19.05 and a 52 week high of $26.58. The company has a market capitalization of $3.05 billion, a PE ratio of 14.76, a price-to-earnings-growth ratio of 0.74 and a beta of 0.67. The company's 50-day simple moving average is $24.20 and its 200 day simple moving average is $23.01.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CPRX. Citigroup increased their price objective on shares of Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the company a "buy" rating in a research report on Tuesday, March 3rd. Zacks Research upgraded shares of Catalyst Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, March 3rd. Truist Financial upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, March 25th. Weiss Ratings reaffirmed a "buy (b-)" rating on shares of Catalyst Pharmaceuticals in a research report on Friday, March 27th. Finally, Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Friday, March 27th. Three investment analysts have rated the stock with a Strong Buy rating and three have given a Buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Strong Buy" and an average target price of $34.00.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company's mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company's lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.